Literature DB >> 23824357

The common PARK8 mutation LRRK2G²⁰¹⁹S is not a risk factor for breast cancer in the absence of Parkinson's disease.

H Mortiboys, A Cox, I W Brock, O Bandmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23824357     DOI： 10.1007/s00415-013-7027-7

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  13 in total

1.  Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease.

Authors:  Kathrine Rugbjerg; Søren Friis; Christina Funch Lassen; Beate Ritz; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2012-03-22       Impact factor: 7.396

2.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas.

Authors:  Brendan D Looyenga; Kyle A Furge; Karl J Dykema; Julie Koeman; Pamela J Swiatek; Thomas J Giordano; Andrew B West; James H Resau; Bin T Teh; Jeffrey P MacKeigan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-10       Impact factor: 11.205

4.  LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.

Authors:  Rachel Saunders-Pullman; Matthew J Barrett; Kaili M Stanley; Marta San Luciano; Vicki Shanker; Lawrence Severt; Ann Hunt; Deborah Raymond; Laurie J Ozelius; Susan B Bressman
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

5.  High prevalence of malignant melanoma in Israeli patients with Parkinson's disease.

Authors:  R Inzelberg; J M Rabey; E Melamed; R Djaldetti; A Reches; S Badarny; S Hassin-Baer; O Cohen; H Trau; J Aharon-Peretz; R Milo; M Schwartz; M Huberman; L Gilead; M Barchana; I Liphshiz; C Fitzer-Attas; N Giladi
Journal:  J Neural Transm (Vienna)       Date:  2011-02-05       Impact factor: 3.575

Review 6.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Authors:  Mark R Cookson
Journal:  Nat Rev Neurosci       Date:  2010-11-19       Impact factor: 34.870

7.  The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.

Authors:  R Inzelberg; O S Cohen; J Aharon-Peretz; I Schlesinger; R Gershoni-Baruch; R Djaldetti; Z Nitsan; L Ephraty; O Tunkel; E Kozlova; L Inzelberg; N Kaplan; T Fixler Mehr; A Mory; E Dagan; E Schechtman; E Friedman; S Hassin-Baer
Journal:  Neurology       Date:  2012-02-08       Impact factor: 9.910

Review 8.  The Roco protein family: a functional perspective.

Authors:  Ignacio Marín; Wouter N van Egmond; Peter J M van Haastert
Journal:  FASEB J       Date:  2008-06-03       Impact factor: 5.191

9.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

Review 10.  Cancer and neurodegeneration: between the devil and the deep blue sea.

Authors:  Hélène Plun-Favreau; Patrick A Lewis; John Hardy; L Miguel Martins; Nicholas W Wood
Journal:  PLoS Genet       Date:  2010-12-23       Impact factor: 5.917
View more
  4 in total

1.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

2.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

3.  Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions.

Authors:  Rohini Raman; Scott P Allen; Emily F Goodall; Shelley Kramer; Lize-Linde Ponger; Paul R Heath; Marta Milo; Hannah C Hollinger; Theresa Walsh; J Robin Highley; Simon Olpin; Christopher J McDermott; Pamela J Shaw; Janine Kirby
Journal:  Neuropathol Appl Neurobiol       Date:  2015-02       Impact factor: 8.090

4.  Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease.

Authors:  Bjørg Johanne Warø; Jan O Aasly
Journal:  Brain Behav       Date:  2017-12-07       Impact factor: 2.708
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.